Europe Pancreatic Cancer Diagnostic Market Size - By Product, By Test Type, By Cancer Type, By End Use, Growth Forecast, 2025 - 2034

Europe Pancreatic Cancer Diagnostic Market Size

The Europe pancreatic cancer diagnostic market was estimated at USD 749.3 million in 2024. The market is expected to grow from USD 793.3 million in 2025 to USD 1.43 billion in 2034, growing at a CAGR of 6.8%, according to the latest report published by Global Market Insights Inc.

The market is steadily growing, driven by the rising prevalence of pancreatitis and pancreatic cancer, advancements in diagnostic technologies, growing healthcare expenditure, and growing awareness and screening initiatives.
 

Pancreatic cancer diagnosis employs a range of techniques and technologies that aim to diagnose pancreatic cancer at various stages. These involve cutting-edge imaging technologies, biomarker tests, molecular diagnostics, and biopsy methods, which are instrumental in establishing malignancy and informing treatment strategies. These technologies are particularly significant in that pancreatic cancer is usually asymptomatic during its initial stages and extremely lethal upon late diagnosis.
 

The market grew from USD 627.4 million in 2021 to USD 706.2 million in 2023, largely due to rising cases of pancreatitis and pancreatic cancer and growing awareness and screening initiatives. Rising efforts to detect pancreatic cancer early are boosting demand for advanced diagnostic tools across Europe. As healthcare systems focus more on identifying high-risk individuals and introducing routine surveillance, the need for imaging technologies, biomarker tests, and molecular diagnostics continues to grow. These developments are improving patient outcomes and encouraging innovation and investment, helping shape a stronger and more competitive market for pancreatic cancer diagnostics.
 

The rising incidence of pancreatitis and pancreatic cancer is significantly contributing to the growth of the diagnostic market in Europe. In 2020, according to the data obtained from European Cancer Information System (ECIS), Europe reported 47,764 new cases of pancreatic cancer and 44,727 deaths from the disease. The lifetime risk of developing pancreatic cancer is estimated at 1 in 91 for men and 1 in 125 for women. It is considered to be the fourth leading cause of cancer-related death in Europe, following lung, colorectal, and breast cancers.
 

This growing disease burden presents a significant market opportunity for innovative, non-invasive, and precision-driven diagnostic technologies. The European pancreatic cancer diagnostics market is expected to grow significantly as healthcare systems focus on early detection and personalized treatment. This growth is supported by advancements in diagnostic technologies, favorable regulatory policies, and rising awareness of public health needs.
 

Furthermore, growing healthcare expenditure across Europe is playing a pivotal role in accelerating the pancreatic cancer diagnostics market. As governments and private sectors increase investments in healthcare infrastructure, there is a stronger emphasis on early detection and precision diagnostics for high-mortality diseases like pancreatic cancer. This financial commitment is enabling the adoption of advanced diagnostic technologies such as liquid biopsy, AI-enhanced imaging, and genomic testing. As a result, the market is witnessing greater accessibility, innovation, and demand for accurate and timely pancreatic cancer diagnostics.
 

Pancreatic cancer diagnostics include a variety of medical tests, imaging technologies, and molecular tools designed to detect, confirm, and monitor the disease. These diagnostic are vital for identifying cancerous cells in the pancreas, determining the stage of the disease, and guiding treatment decisions effectively.

Europe Pancreatic Cancer Diagnostic Market Trends

• Advancements in diagnostic technologies are significantly reshaping the pancreatic cancer diagnostics industry in Europe. Recent innovations are improving detection accuracy, speed, and accessibility, leading to better patient outcomes and expanding market opportunities.
   
• Next-Generation Sequencing (NGS) is a transformative technology in cancer diagnostics, enabling high-throughput and precise analysis of genetic mutations associated with various cancers, including pancreatic cancer.  Agilent Technologies offers the SureSelect Cancer Tumor-Specific Assays, a targeted NGS solution specifically designed for profiling genetic alterations in pancreatic tumors. These assays can detect critical mutations such as KRAS, TP53, and BRCA2, which are commonly linked to pancreatic cancer progression and treatment resistance.
   
• The adoption of AI-driven imaging technologies marks a significant advancement in medical diagnostics. Leading companies like Siemens Healthineers and GE Healthcare have developed sophisticated CT and MRI systems that incorporate artificial intelligence to improve image clarity, streamline lesion identification, and shorten scanning durations, resulting in enhanced diagnostic performance.
   
• A prime example is GE Healthcare’s SIGNA Champion 1.5T MRI Scanner, an innovative tool tailored for precision in pancreatic cancer diagnosis. Featuring AI-enhanced solutions such as AIR Recon DL and Sonic DL, it produces high-definition images while significantly cutting down scan time.
   
• Leading companies across Europe are integrating NGS, biomarker assays, and liquid biopsy technologies to enhance diagnostic precision and promote personalized care. These innovations are expected to contribute to better survival outcomes as the healthcare focus shifts toward early and accurate detection.
   

Europe Pancreatic Cancer Diagnostic Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The Europe pancreatic cancer diagnostic market was valued at USD 627.4 million in 2021. The market size reached USD 749.3 million in 2024, from USD 706.2 million in 2023.  
 

Based on the product, the market is segmented into instruments and consumables. The consumables segment led this market in 2024, accounting for the highest market share because of its high demand for reagents and assay kits and the growing adoption of liquid biopsy and molecular testing techniques. This segment was valued at USD 427.8 million in 2024 and is projected to reach USD 804.6 million by 2034, growing at a CAGR of 6.6%. This growth is due to the continuous need for repeat testing, rising adoption of personalized medicine, and the increasing use of consumables in advanced diagnostic techniques such as liquid biopsy, molecular profiling, and immunoassays.
 

In comparison, the instruments segment, valued at USD 321.5 million in 2024, is expected to grow to USD 628.6 million by 2034, with a slightly higher CAGR of 7%, supported by continuous technological innovations, increasing adoption of AI-powered imaging systems, and rising demand for advanced diagnostic equipment in hospitals and diagnostic imaging centers.
 

• Consumables in pancreatic cancer diagnostics refer to reagents, assay kits, and buffers that are essential for conducting diagnostic tests. These products are used across various modalities including molecular diagnostics, immunoassays, and image-guided biopsies.
   
• The growth of the consumables segment is fueled by the adoption of advanced diagnostic technologies such as next-generation sequencing (NGS), liquid biopsy, and multiplex immunoassays. These technologies require high-quality disease-specific reagents and kits for accurate detection of biomarkers like KRAS, CA 19-9, and BRCA2.
   
• The QIAseq Targeted DNA Pro Human Hereditary Pancreatic Cancer Panel by QIAGEN is a specialized next-generation sequencing (NGS) kit designed for the detection of genetic mutations associated with hereditary pancreatic cancer. This kit targets all exons of key genes such as BRCA1, BRCA2, PALB2, CDKN2A, and TP53. The panel is particularly valuable for early risk assessment and personalized treatment planning in individuals with a family history of pancreatic cancer.
   
• With continuous innovation in molecular and immunoassay technologies, and increasing clinical demand for early detection, consumables will remain a cornerstone of diagnostic workflows. 
   

Based on the test type, the Europe pancreatic cancer diagnostic market is segmented into imaging test, biopsy, blood test, and other test type. The imaging test segment accounted for the highest market share of 60.9% in 2024.
 

• Imaging tests such as CT scans and MRI play a critical role in the diagnosis and staging of pancreatic cancer. These modalities allow clinicians to visualize the pancreas, which is located deep within the abdomen and surrounded by other organs, offering detailed anatomical views without the need for invasive procedures. This capability is essential for identifying tumors, assessing their extent, and planning appropriate treatment strategies.
   
• Advanced imaging systems are enhancing diagnostic precision. For instance, the Aquilion ONE / PRISM Edition by Canon Medical Systems offers advanced imaging capabilities that support precision in pancreatic cancer diagnostics. It integrates AI-powered technologies such as the Advanced intelligent Clear-IQ Engine (AiCE) and Precise IQ Engine (PIQE) to deliver high-resolution, low-noise images with minimal radiation exposure, enabling clearer visualization of pancreatic lesions and surrounding structures.
   
• In addition to initial diagnosis, imaging technologies are instrumental in guiding procedures such as fine-needle aspiration biopsies and surgical interventions. Techniques like endoscopic ultrasound (EUS) and MRI help pinpoint tumor location and size, ensuring precise sampling and minimizing procedural risks.
   
• These imaging advancements enhance diagnostic precision and facilitate personalized treatment planning, thereby playing a crucial role in driving the growth of the pancreatic cancer diagnostics market across Europe.
   

Based on the cancer type, the Europe pancreatic cancer diagnostic market is segmented into exocrine and endocrine. The exocrine segment accounted for the highest market share of 93.3% in 2024.
 

• The pancreatic cancer diagnostics segment is witnessing robust growth, fueled by the rising prevalence of exocrine pancreatic cancers, including adenocarcinoma, colloid carcinoma, adenosquamous carcinoma, and squamous cell carcinoma.
   
• Adenocarcinoma is the most common type of pancreatic cancer.  It accounts for about 90% of all pancreatic cancers.  It starts with the cells lining the pancreatic duct.
   
• The rising prevalence of exocrine pancreatic cancers including adenocarcinoma, colloid carcinoma, adenosquamous carcinoma, and squamous cell carcinoma is driving an urgent need for advanced technologies that enable early detection, precise staging, and personalized treatment planning.
   
• Additionally, rapid technological innovation is transforming diagnostic workflows. Breakthroughs such as AI-enhanced imaging, cryo-biopsy methods, and automated lesion detection are significantly improving diagnostic accuracy, reducing turnaround times, and elevating patient safety and comfort. These advancements are accelerating the adoption of next-generation diagnostic tools and propelling the expansion of the pancreatic cancer diagnostics market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the Europe pancreatic cancer diagnostic market is segmented into cancer research institutes, hospitals and clinics, diagnostic laboratories, and diagnostic imaging centers. Cancer research institutes are growing at highest CAGR of 7.3% through 2034.
 

• Cancer research institutes play a pivotal role in shaping the pancreatic cancer diagnostic market by driving advancements in early detection technologies, biomarker discovery, and imaging techniques.
   
• Their work has led to the development of more sensitive and specific diagnostic tools, enabling clinicians to identify pancreatic cancer at earlier stages, which is crucial given the disease’s typically late presentation and poor prognosis.
   
• For instance, The Organisation of European Cancer Institutes (OECI) is a collaborative network comprising over 120 premier cancer research centers across Europe. The primary objective of the OECI is to advance multidisciplinary and personalized cancer care across Europe. Through fostering collaboration, innovation, and knowledge exchange among its members, the organization strives to ensure equitable access to high-quality cancer treatment for all patients.
   
• Thus, the growing number of cancer research institutes, along with increased emphasis on awareness and screening initiatives, is further fueling market growth.
   

Looking for region specific data?

Download Free PDF

Germany dominated the pancreatic cancer diagnostics market with the highest market share of 20.8% in 2024. The region has advanced healthcare infrastructure and a growing focus on early and accurate diagnosis. Further, there is an increasing prevalence of pancreatitis in Europe thus propelling the growth of this market.
 

• Germany pancreatic cancer diagnostic market was valued at USD 128.3 million and USD 137 million in 2021 and 2022, respectively. In 2024, the market size reached USD 156 million from USD 146.1 million in 2023.
   
• The rising incidence of pancreatic cancer in Germany is a significant driver of market growth.
   
• For instance, data from Germany’s official cancer registry indicates that in 2020, pancreatic cancer accounted for approximately 20,230 cases annually in Germany, with a nearly equal distribution between men and women, and results in around 18,922 deaths.
   
• As the fourth leading cause of cancer-related mortality in the country, its poor prognosis largely due to late-stage diagnosis and rapid disease progression has intensified the demand for improved diagnostic and therapeutic solutions.
   
• Therefore, as the number of pancreatic cancer cases increases, the demand for effective and technologically advanced diagnostic solutions for early detection and staging of cancer also rises, thereby accelerating market growth in the country.
   

UK pancreatic cancer diagnostic market accounted for USD 102.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The UK is witnessing notable growth in its pancreatic cancer diagnostics market, driven by a combination of strategic screening initiatives and heightened public awareness.
   
• For example, one of the most impactful efforts is the UK Early Detection Initiative (UK-EDI). By collecting blood samples and clinical data every six months over a multi-year period, UK-EDI aims to identify biomarkers that can distinguish pancreatic cancer associated diabetes from standard type 2 diabetes. This targeted approach not only enhances early detection but also lays the foundation for a future screening program tailored to high-risk populations. Thus, growing emphasis on awareness and screening initiative is significantly boosting the market
   

France is projected to be valued at USD 117.4 million in 2024 and is expected to reach USD 244.3 million by 2034.
 

• The pancreatic cancer diagnostic market in France is expanding rapidly due to the growing burden of pancreatic cancer, rising health awareness, and continuous advancements in diagnostic solutions for pancreatic cancer.
   
• For instance, according to the Institut National du Cancer (INCa), 15,991 cases of pancreatic cancer were confirmed in 2023, making France the fourth-most affected country globally. This marked a dramatic increase from just 3,700 cases in 1990, with annual growth rates of 2–3% in diagnoses between 2010 and 2023. These statistics indicates growing need for pancreatic cancer diagnostic for early detection and better patient outcomes.
   

Italy pancreatic cancer diagnostic market is poised to witness lucrative growth between 2025-2034, growing at CAGR of 7.0%.
 

• Italian healthcare landscape is witnessing a notable surge in pancreatic cancer cases, with KRAS mutations emerging as a key molecular driver. Over 90% of pancreatic ductal adenocarcinoma (PDAC) cases in Italy exhibit KRAS mutations, particularly subtypes like G12D, G12V, and G12R, which are associated with aggressive tumor behavior and poor prognosis.
   
• This growing awareness and identification of KRAS mutations among the Italian population is fueling demand for advanced diagnostic tools, targeted therapies, and personalized treatment approaches.
   
• In response to this clinical need, Italy is actively participating in cutting-edge research and clinical trials. One prominent example is the RASolute 302 trial, which is currently recruiting Italian patients with metastatic pancreatic cancer. This trial focuses on KRAS-targeted therapies, marking a significant step toward precision medicine in the country.
   
• The convergence of rising disease burden, molecular profiling, and clinical innovation is positioning Italy as a key player in market.
   

Spain is experiencing significant growth in the pancreatic cancer diagnostic market, driven by the advancements in diagnostic technologies and growing healthcare expenditure.
 

• In 2021, Spain's healthcare expenditure amounted to approximately USD 4,368 per capita (PPP), reflecting a steady increase in national health spending. This upward trend is primarily driven by demographic shifts such as an aging population, which necessitates more frequent and complex medical care, alongside a growing burden of chronic disease like pancreatic cancer which requires long-term management.
   
• Additionally, advancements in medical diagnostic technology and increased public awareness are further fueling growth of this market.
   

The Netherlands pancreatic cancer diagnostic market is expected to experience significant and promising growth from 2025 to 2034.
 

• The government of Netherlands is significantly investing in healthcare infrastructure to incorporate advanced diagnostic solutions within hospital settings, aiming to provide the utmost care to individuals suffering from chronic conditions in the country.
   
• Additionally, ongoing innovations such as AI-powered imaging, liquid biopsy techniques, and precision molecular diagnostics have enhanced diagnostic accuracy, reduced procedural risks, and improved patient outcomes, significantly reshaping the market.
   

Europe Pancreatic Cancer Diagnostic Market Share

• The top five players, such as GE Healthcare, Siemens Healthineers, F. Hoffmann-La Roche, Thermo Fisher Scientific, and QIAGEN, collectively held 70% of the total market share. These players are continuing to strengthen their positions through innovation, regulation, and strategic collaborations.
   
• Leading companies in the Europe pancreatic cancer diagnostics landscape are actively reinforcing their market positions through technological innovation, regulatory alignment, and strategic partnerships. These players are emphasizing innovations in biopsy, assays and next-generation diagnostic tools that enhance precision, real-time imaging, and minimally invasive procedures, in line with evolving clinical demands across Europe.
   
• For instance, Abbott’s ARCHITECT CA 19-9XR assay, a high-sensitivity immunoassay, quantitatively determines the CA 19-9 tumor marker, aiding in the detection and monitoring of pancreatic cancer. Its reliable performance and seamless integration into routine diagnostics bolster clinical decision-making and patient management.
   
• Thermo Fisher Scientific continues to hold a prominent role in the European segment, driven by its Oncomine platform, which combines liquid biopsy assays with next-generation sequencing (NGS) for highly sensitive detection of tumor-derived DNA and RNA. The company is advancing compact sequencing technologies, AI-powered bioinformatics, and low-input nucleic acid workflows to support early-stage diagnosis and improve clinical outcomes.
   

Europe Pancreatic Cancer Diagnostic Market Companies

Few of the prominent players operating in the Europe pancreatic cancer diagnostic industry include:

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Canon
• Danaher Corporation
• Esaote
• F Hoffmann-La Roche
• GE Healthcare
• Hitachi
• Illumina
• Koninklijke Philips
• Myriad Genetics
• Olympus Corporation
• QIAGEN
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
   

• GE HealthCare

GE HealthCare has a strong global workforce of approximately 51,000 employees, which enables the company to drive innovation and deliver high-quality solutions. With innovations in PET, SPECT, and AI-powered imaging systems, GE supports early detection and personalized treatment strategies across European healthcare settings.
 

• Agilent Technologies

Agilent Technologies plays a growing role in Europe's precision oncology landscape, particularly through its advanced NGS-based assays that support pancreatic cancer research and diagnostics. One of its key offerings is the SureSelect Cancer Tumor-Specific Assay, which includes panels tailored for pancreatic tissue profiling.
 

• Siemens Healthineers

Siemens Healthineers plays a pivotal role in the European diagnostics landscape, particularly in pancreatic cancer detection. With a robust research and development infrastructure and a commitment to innovation, the company offers cutting-edge imaging technologies, AI-enhanced diagnostic tools, and user-centric designs tailored to meet the evolving needs of European healthcare providers.
 

Europe Pancreatic Cancer Diagnostic Industry News:

• In July 2024, Koninklijke Philips received FDA 510(k) clearance for its SmartSpeed Precise Dual AI software, enabling up to 3x faster MRI scans and 80% sharper images. This AI-powered solution enhances workflow efficiency and diagnostic accuracy across Philips’ 1.5T and 3.0T MRI systems, reinforcing its commitment to precision imaging and scalable diagnostics.
   
• In September 2024, Canon Medical Systems and Olympus Corporation partnered to launch the Aplio i800 EUS system in Europe, a high-resolution endoscopic ultrasound (EUS) platform designed for advanced imaging of pancreatic lesions and other gastrointestinal conditions. This system integrated Canon’s Aplio i800 ultrasound technology with Olympus’s endoscopic expertise, offering enhanced image clarity, precision-guided biopsies, and improved diagnostic confidence for clinicians. The collaboration aimed to support early detection and better management of pancreatic diseases, including cancer, across European healthcare settings.
   

The pancreatic cancer diagnostic market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables

Market, By Test Type

• Imaging test
  • CT scan
  • MRI
  • Ultrasound
  • PET
  • Other imaging tests
• Biopsy
• Blood test
  • Liver function tests
  • Tumor markers
  • Other blood tests
• Other test types

Market, By Cancer Type

• Exocrine
  • Adenocarcinoma
  • Colloid carcinoma
  • Adenosquamous carcinoma
  • Squamous cell carcinoma
• Endocrine

Market, By End Use

• Cancer research institutes
• Hospitals and clinics
• Diagnostic laboratories
• Diagnostic imaging centers

The above information is provided for the following countries:

• Germany
• UK
• France
• Italy
• Spain
• Netherlands